News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups
Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups
Hosted by Robert Michel
Sign In

Harvard Researchers Create Chip-based, Liquid Biopsy Device That Offers a Novel Way to Monitor Treatment of Ovarian Cancer Patients and Only Costs $1

Feb 14, 2014 | Instruments & Equipment, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology

The ATC Chip identifies ovarian cancer cells floating in ascites and may be useful for diagnosing other types of malignancies that involve ascites, like pancreatic cancer

Pathologists will be interested to learn that researchers at Harvard Medical School and Massachusetts General Hospital are developing a “liquid biopsy” technology specifically to enable point-of-care monitoring of the progress of patients undergoing treatment for certain types of cancers.

The goal is to develop a method that community hospitals can use to monitor treatment of ovarian cancer patients without the need for expensive medical laboratory equipment, noted a report published by Biosciencetechnology.com. Researchers estimate that their ‘liquid biopsy’ technology could cost as little as $1 per test when eventually cleared for use in clinical settings.
(more…)

Researchers Determine That Individuals’ ‘Breathprint’ Are Unique; May Have Potential for Clinical Laboratory Testing When Coupled With Mass Spectrometry Technology

Oct 14, 2013 | Instruments & Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Pathology

Pathologists may be interested to learn that everyone’s breath reveals a signature composition of metabolites that may reflect a lifetime of diet, state of health, illnesses, and exposure to chemicals

New research shows that a person’s “breathprint” is as unique as a fingerprint and may be as effective as bodily fluids in diagnosing diseases. That same research effort is showing that it is feasible to combine breath specimens and mass spectrometry to accurately identify disease. That could give clinical laboratories a new methodology to use when creating diagnostic assays.

These findings are part of a new study conducted by researchers at the Swiss Federal Institute of Technology (ETH Zurich) in Zurich. The study was published by the journal PLOS ONE. (more…)

;